Recent Updates
Recently added Catalysts
RIGL Positive Sentiment Score: 65/100

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Friday, January 3, 2025 1 min read
Key Takeaway: Rigel Pharmaceuticals, Inc. has announced the granting of inducement awards under NASDAQ Listing Rule 5635(c)(4). As part of this initiative, the company awarded 46,131 stock options to eight non-executive employees. These options will vest over a four-year period with a one-year cliff. This move highlights Rigel's strategy to attract and retain talent as it continues to develop therapies for hematologic disorders and cancer.

Market Sentiment Analysis

POSITIVE FACTORS

  • Rigel granted 46,131 stock options to attract non-executive talent.
  • Inducement grants align with company's growth strategy and development efforts.
  • Rigel is committed to improving lives through novel therapies.

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Jan. 3, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 46,131 stock options to eight non-executive employees vesting over four years with a one-year cliff.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, its marketed products and pipeline of potential products, please visit www.rigel.com.
Contact for Investors & Media
Rigel Pharmaceuticals, Inc.
SOURCE Rigel Pharmaceuticals, Inc.

21 %

more press release views with

Frequently Asked Questions

What stock options did Rigel Pharmaceuticals grant?

Rigel granted 46,131 stock options to eight non-executive employees.

How long is the vesting period for Rigel's stock options?

The stock options vest over four years with a one-year cliff.

What is the focus of Rigel Pharmaceuticals?

Rigel focuses on therapies for hematologic disorders and cancer.

When was Rigel Pharmaceuticals founded?

Rigel Pharmaceuticals was founded in 1996.

Where is Rigel Pharmaceuticals located?

Rigel Pharmaceuticals is based in South San Francisco, California.

Tags: RIGL Viatris Investor Conferences Healthcare Rigel Pharmaceuticals inducement grants NASDAQ stock options biotechnology
Last updated: Jan 3, 2025